Michael Steven Hershfield

Conference Blood · October 14, 2021 Patients lacking functional adenosine deaminase activity have severe combined immunodeficiency (ADA SCID), which can be treated with ADA enzyme replacement therapy (ERT), allogeneic hematopoietic stem cell transplantation (HSCT), or autologous HSCT with ge ... Full text Link to item Cite

30. Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID) Using a γ-Retroviral Vector

Conference Molecular Therapy · May 2015 Full text Cite

HSCT Rescues the Immunological and Vascular Phenotype of ADA2-Deficiency

Conference JOURNAL OF CLINICAL IMMUNOLOGY · October 1, 2014 Link to item Cite

LATE-ONSET PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY WITH SPASTIC PARAPLEGIA

Conference JOURNAL OF CLINICAL IMMUNOLOGY · August 1, 2014 Link to item Cite

LATE-ONSET PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY WITH SPASTIC PARAPLEGIA

Conference JOURNAL OF CLINICAL IMMUNOLOGY · August 1, 2014 Link to item Cite

Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID)

Conference MOLECULAR THERAPY · May 1, 2014 Link to item Cite

Impulse Oscillometry (IOS) Reveals Increased Pulmonary Impedence in Children with Adenosine Deaminase-Deficient Severe Combined Immunodeficiency (ADA-SCID)

Conference JOURNAL OF CLINICAL IMMUNOLOGY · April 1, 2014 Link to item Cite

A 22-YEAR REPLACEMENT THERAPY FOR AN ADENOSINE DEAMINASE (ADA) DEFICIENT PATIENT

Conference ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY · November 1, 2013 Link to item Cite

SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADENOSINE DEAMINASE DEFICIENCY: EVIDENCE FROM THREE CASE REPORTS

Conference JOURNAL OF CLINICAL IMMUNOLOGY · April 1, 2013 Link to item Cite

US RESULTS OF GENE THERAPY FOR ADENOSINE DEAMINASE DEFICIENCY

Conference JOURNAL OF CLINICAL IMMUNOLOGY · September 1, 2012 Link to item Cite

FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment

Conference Annals of the Rheumatic Diseases · June 2012 Full text Cite

FRI0372 Pharmacokinetics and immunogenicity of pegloticase (PL) infused every 3 weeks to treat refractory gout (RG), including in organ transplant recipients (TR)

Conference Annals of the Rheumatic Diseases · June 2012 Full text Cite

Systemic Effects of PEG-ADA Withdrawal with or Without Chemotherapy (CHTX) and Cytotherapy (CTX) in Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID)

Conference JOURNAL OF CLINICAL IMMUNOLOGY · April 1, 2012 Link to item Cite

307 HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERON

Conference Journal of Hepatology · April 2010 Full text Cite

Immune Reconstitution after Gene Therapy for Adenosine Deaminase Deficient Severe Combined Immune Deficiency (ADA-SCID)

Conference MOLECULAR THERAPY · May 1, 2009 Link to item Cite

The Pattern of Joint Involvement in Patients with Treatment Failure Gout

Conference ARTHRITIS AND RHEUMATISM · December 1, 2008 Link to item Cite

Steady ongoing hematological and immunological reconstitution achieved in ADA-deficiency patients treated by stem cell gene therapy with no myelopreparative conditioning

Conference JOURNAL OF GENE MEDICINE · December 1, 2006 Link to item Cite

Measurement of exchangeable uric acid pool size: Potential utility for evaluating the therapy of gout.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2006 Link to item Cite

1088. Stem Cell Gene Therapy with No Pre-Conditioning for the ADA-Deficiency Patients Leads to Generalized Detoxification and Delayed, but Steady Hematological Reconstitution

Conference Molecular Therapy · 2006 Full text Cite

A Phase I study of pegylated-uricase (Puricase (R)) in subjects with gout.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2004 Link to item Cite

Antibodies to polyethylene glycol (PEG) during Phase I investigation of PEG-(R)) for refractory gout

Conference ARTHRITIS AND RHEUMATISM · September 1, 2004 Link to item Cite

Severe gout is associated with impaired quality of life and functional status.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2004 Link to item Cite

Corrective gene transfer into bone marrow CD34+cells for adenosine deaminase (ADA) deficiency: Results in four patients after one year of follow-up

Conference MOLECULAR THERAPY · May 1, 2003 Link to item Cite

Discontinuation of PEG-ADA replacement therapy in a patient with ADA-deficiency previously treated with retroviral-mediated, T cell-directed gene therapy

Conference MOLECULAR THERAPY · May 1, 2003 Link to item Cite

Clinical evaluation of retroviral vectors for corrective gene transfer of adenosine deaminase (ADA) deficiency.

Conference BLOOD · November 16, 2002 Link to item Cite

Severe morbidity associated with refractory gout.

Conference ARTHRITIS AND RHEUMATISM · September 1, 2002 Link to item Cite

Clinical evaluation of retroviral vectors for gene therapy of adenosine deaminase (ADA) deficiency.

Conference CLINICAL IMMUNOLOGY · June 1, 2002 Link to item Cite

Loss of adenosine deaminase activity inhibits beta selection in murine fetal thymic organ culture

Conference FASEB Journal · March 20, 1998 Murine fetal thymic organ cultures (FTOC) treated with the ADA inhibitor 2′-deoxycoformycin (dCF) were used as a model system to investigate the mechanism by which T cell differentiation is inhibited in adenosine deaminase (ADA)-deficient humans. The metab ... Cite

Biochemistry and immunology of polyethylene glycol-modified adenosine deaminase (PEG-ADA)

Conference ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY · April 13, 1997 Link to item Cite

POSSIBLE MECHANISMS FOR THE ANTI-HIV ACTIVITY OF 3-DEAZA-ADENOSINE (DZA) ANALOGS

Conference FASEB JOURNAL · April 24, 1995 Link to item Cite

PROLONGED DIRECT HYPERBILIRUBINEMIA AS A PRESENTATION OF ADENOSINE-DEAMINASE DEFICIENCY

Conference JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY · January 1, 1995 Link to item Cite

ANALYSIS OF THE RELATIONSHIP OF GENOTYPE TO PHENOTYPE IN ADENOSINE-DEAMINASE (ADA) DEFICIENT PATIENTS UNDERGOING TREATMENT WITH POLYETHYLENE GLYCOL-MODIFIED ADENOSINE-DEAMINASE (PEG-ADA)

Conference CLINICAL RESEARCH · April 1, 1994 Link to item Cite

GENE-THERAPY FOR NEONATES WITH ADENOSINE-DEAMINASE (ADA) DEFICIENT SCID BY RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN ADA CDNA INTO UMBILICAL-CORD CD34+ CELLS

Conference PEDIATRIC RESEARCH · April 1, 1994 Link to item Cite

GENE-THERAPY FOR NEONATES WITH ADA-DEFICIENT SCID BY RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN ADA CDNA INTO UMBILICAL-CORD CD34+ CELLS

Conference JOURNAL OF CELLULAR BIOCHEMISTRY · January 4, 1994 Link to item Cite

New therapies for adenosine deaminase deficiency: Difficult choices, some problems with evaluation

Conference Clinical Immunology Newsletter · January 1, 1994 Full text Cite

GENE-THERAPY FOR NEONATES WITH ADA-DEFICIENT SCID BY RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN ADA CDNA INTO UMBILICAL-CORD CD34+ CELLS

Conference BLOOD · November 15, 1993 Link to item Cite

HEMATOPOIETIC ENGRAFTMENT FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) WITHOUT CYTOREDUCTION IN A CHILD WITH SEVERE COMBINED IMMUNE-DEFICIENCY (SCID)

Conference BLOOD · November 15, 1993 Link to item Cite

ENZYME REPLACEMENT THERAPY WITH POLYETHYLENE GLYCOL-ADENOSINE DEAMINASE IN ADENOSINE-DEAMINASE DEFICIENCY - OVERVIEW AND CASE-REPORTS OF 3 PATIENTS, INCLUDING 2 NOW RECEIVING GENE-THERAPY

Conference PEDIATRIC RESEARCH · January 1, 1993 Link to item Cite

Design, anti-hiv activity, cellular pharmacology and conformation of BCH-189 [(±)3TC], a novel nucleoside analogue

Conference · January 1, 1992 Reverse transcriptase is an attractive target and nucleoside analogues probably still represent today one of the most promising classes of compounds for the treatment of HIV infection. Chemists at IAF BioChem have devised a novel chemical strategy leading ... Full text Cite